A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01424618|
Recruitment Status : Unknown
Verified August 2011 by Maureen Kelly, M.D., Kelly, Maureen, M.D..
Recruitment status was: Recruiting
First Posted : August 29, 2011
Last Update Posted : August 29, 2011
This study compares two different methods to prepare the uterine lining of recipients for implantation in cycles using donor eggs. The study method requires less time than the standard method.
It is hypothesized that both methods would be suitable for use in egg donor cycles.
|Condition or disease||Intervention/treatment||Phase|
|Implantation, Embryo||Drug: Leuprolide Drug: Ganirelix||Not Applicable|
Currently a combination of medications is used to prepare the uterine lining of recipients for implantation in egg donor cycles. The protocol used most commonly is as follows: Initially the individual's own pituitary-ovarian system is suppressed using a GnRH agonist so there are not conflicting signals sent to the uterus. This is followed by hormonal medication identical to what is secreted by the ovaries to prepare the uterine lining for subsequent embryo transfer in donor egg cycles.This preparation typically takes a minimum of four weeks.
This study will compare a different medication, a GnRh antagonist (which is commonly used in IVF) to suppress an individual's system during the preparation of the uterine lining. This protocol would generally take only two weeks to prepare the uterine lining.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Novel Approach to Endometrial Preparation in Recipients of Donor Cycles|
|Study Start Date :||January 2006|
|Estimated Primary Completion Date :||September 2012|
Active Comparator: GnRh agonist
This arm will use a GnRH agonist to suppress pituitary-ovarian function
leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
Other Name: Lupron
Experimental: GnRH antagonist
A GnRH antagonist will be used to suppress pituitary-ovarian function
Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
Other Name: Antagon
- endometrial thickness measured by ultrasound [ Time Frame: 2-4 weeks ]In office ultrasound to measure thickness of endometrial lining.
- endometrial biopsy [ Time Frame: 3-6 weeks ]In office aspiration of endometrial cells will be examined microscopically to determine if they are at an appropriate stage for implantation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01424618
|Contact: Dana Tillotson, BSNemail@example.com|
|United States, Pennsylvania|
|Society Hill Reproductive Medicine||Recruiting|
|Philadelphia, Pennsylvania, United States, 19107|
|Contact: Dana Tillotson, BSN 215-829-8110 firstname.lastname@example.org|
|Principal Investigator: Maureen Kelly, MD|
|Principal Investigator:||Maureen Kelly, MD||Society Hill Reproductive Medicine|